Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

DRonabinol Behandling av OSA (DROSA)

2. november 2026 oppdatert av: VA Office of Research and Development

Målrettet behandling av obstruktiv søvnapné med dronabinol: Proof of Concept og fase II klinisk studie

This is an open-label trial that tests the effectiveness of Dronabinol in treating obstructive sleep apnea (OSA). All participants will take oral Dronabinol for two weeks. Sleep studies will be conducted before and after treatment to measure OSA severity.

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Detaljert beskrivelse

Obstructive sleep apnea (OSA), is a serious respiratory disorder that involves repetitive cessation of breathing during sleep. It is estimated that 15-20 million people in the United States suffer from OSAS, which has been linked to increased risk for hypertension, heart failure, depression, and diabetes. The current standard of care for OSA, positive airway pressure (PAP), involves a mechanical device with low patient tolerance and adherence. Upper airway surgical approaches are also an option but are invasive and often unsuccessful. Effective drug treatments for OSA remain to be identified.

This study will enroll up to 120 Veterans so that 45 Veterans may complete the two-week open-label Dronabinol treatment trials. The results of the study will be used to develop a prediction model for OSA severity reduction after 2-week Dronabinol treatment vs. pretreatment AHI. Participants clinical (age, sex, body mass index, comorbidity) and pretreatment polysomnographic characteristics (sleep architecture, respiratory disturbance, and endotypes; loop-gain, arousal threshold, upper airway collapsibility and compensation) will be used to develop a prediction model for improvement of OSA with Dronabinol treatment. This prediction model will be used for a randomized clinical trial after the completion of this trial.

Studietype

Intervensjonell

Registrering (Antatt)

120

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Illinois
      • Chicago, Illinois, Forente stater, 60612
        • Rekruttering
        • Jesse Brown VA Medical Center, Chicago, IL
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bharati Prasad, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

Ikke eldre enn 65 år (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

1. AHI 15-50 per hour on pre-treatment polysomnography

Exclusion Criteria:

  1. Positive Airway Pressure (PAP) treatment of obstructive sleep apnea (OSA): use > 4 hours per day for 30% of days within 3 months of enrollment. PAP use will be determined from device download data

  2. Hypoglossal nerve stimulator (HNS) or oral appliance device treatment with use > 4 hours per day for 30% of days within 3 months of enrollment. HNS use will be determined by device download and oral appliance use by self-report

  3. History of upper airway surgery for OSA (except adenotonsillectomy)

  4. Central or mixed apneas >25% of respiratory events on diagnostic polysomnography

  5. Arterial oxygen saturation < 75% for > 5% sleep time on pretreatment polysomnography

  6. Body mass index > 45 kilograms per square meter (kg/m2)

  7. If post-bariatric surgery, weight must be stable ±5% (per electronic medical records) for at least 6 months before the first dose of the study drug

  8. Active enrollment in a weight loss program

  9. Shiftwork within 3 months of enrollment

  10. High-risk occupation: commercial driver and pilot

  11. Motor vehicle accident or near-miss incident within 1 year of enrollment

  12. Current drug or habitual alcohol use or positive urine drug screen

  13. Comorbid medical and psychiatric disorders:

    1. Primary sleep disorders: e.g., narcolepsy, restless legs syndrome
    2. Uncontrolled mood disorder or a diagnosis of schizophrenia
    3. Initiation of new antidepressant or antipsychotic medication within 3 months
    4. Identified as high-risk for suicide in electronic health records
    5. Uncontrolled medical disorders (coronary heart disease, arrhythmia, congestive heart failure, chronic obstructive pulmonary disease, chronic hypoxemic or hypercapnic respiratory failure, stroke within 6 months of enrollment, chronic liver or kidney disease, autoimmune disorders)
  14. Use of sedative-hypnotic medications within 30 days of enrollment

  15. Complete blood count or liver function test values more than 1.5 times the upper limit of normal

  16. Pregnancy

  17. Allergy to cannabinoids or sesame oil

  18. Average weekly alcohol consumption of more than 10 servings

  19. Participation in other investigational protocols within 30 days of enrollment

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Single group

Open label Dronabinol treatment for two weeks.

Open label Dronabinol treatment for two weeks.

Andre navn:
  • Marinol

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Apnea Hypopnea Index (AHI)
Tidsramme: 2 weeks

The change in AHI after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms.

2 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
T<90
Tidsramme: 2 weeks

The change in time below 90% oxygen saturation (T<90) after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms.

2 weeks

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Psychomotor Vigilance Test (PVT)
Tidsramme: 2 weeks

The change in Lapses on Psychomotor Vigilance Test (PVT) after two weeks of Dronabinol treatment will be determined from before and after treatment PVT using a 10 minute protocol.

2 weeks
24-hour Mean Arterial Blood Pressure (BP)
Tidsramme: 2 weeks

The change in 24- hour mean arterial blood pressure after two weeks of Dronabinol treatment will be determined from before and after treatment 24-hiur ambulatory BP recording.

2 weeks
Sleep Efficiency
Tidsramme: 2 weeks

The change in sleep efficiency after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms.

2 weeks
Rapid Eye Movement (REM) Sleep
Tidsramme: 2 weeks

The change in REM sleep after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms.

2 weeks
Slow Wave Sleep
Tidsramme: 2 weeks

The change in slow wave sleep after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms.

2 weeks
Treatment Satisfaction Questionnaire for Medication (TSQM)
Tidsramme: 2 weeks

Patient reported treatment satisfaction. TSQM scores have a range of 0 to 100, with higher scores indicating higher satisfaction.

2 weeks
Epworth Sleepiness Scale (ESS)
Tidsramme: 2 weeks

The change in Epworth Sleepiness Scale (ESS) will be measured after two weeks of Dronabinol treatment.

ESS scores have a range of 0 to 24, with higher scores indicating greater sleepiness.

2 weeks
Functional Outcomes of Sleep Questionnaire (FOSQ)
Tidsramme: 2 weeks

The change in Functional Outcomes of Sleep Questionnaire (FOSQ) will be measured after two weeks of Dronabinol treatment.

FOSQ score ranges from 5-20, with higher scores indicating better functional status.

2 weeks
Pittsburgh Sleep Quality Index (PSQI)
Tidsramme: 2 weeks

The change in Pittsburgh Sleep Quality Index (PSQI) will be measured after two weeks of Dronabinol treatment.

The PSQI score ranges from 0 to 21. Higher scores indicate poorer sleep quality.

2 weeks
Insomnia Severity Index (ISI)
Tidsramme: 2 weeks

The change in Insomnia Severity Index (ISI) will be measured after two weeks of Dronabinol treatment.

ISI ranges from 0 to 28, with higher scores indicating greater sleep disturbance.

2 weeks
Post-Traumatic Stress Disorder; PTSD checklist (PCL-5)
Tidsramme: 2 weeks

The change in Post-Traumatic Stress Disorder; PTSD checklist (PCL-5) will be measured after two weeks of Dronabinol treatment.

PCL-5 scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity.

2 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Bharati Prasad, MD, Jesse Brown VA Medical Center, Chicago, IL

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

25. august 2025

Primær fullføring (Antatt)

31. mars 2027

Studiet fullført (Antatt)

31. mars 2027

Datoer for studieregistrering

Først innsendt

21. juni 2024

Først innsendt som oppfylte QC-kriteriene

21. juni 2024

Først lagt ut (Faktiske)

27. juni 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere